Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: Meta-analysis

British Journal of Psychiatry

Volumn 196, Issue 6, 2010, Pages 434-439

  Crossley, Nicolas A ^a   Constante, Miguel ^a   McGuire, Philip ^b   Power, Paddy ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SULPIRIDE; ZIPRASIDONE; ZUCLOPENTHIXOL;

ARTICLE; BODY MASS; CLINICAL TRIAL; COCHRANE LIBRARY; DRUG EFFICACY; DRUG WITHDRAWAL; EMBASE; EVIDENCE BASED PRACTICE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LOW DRUG DOSE; MEDLINE; META ANALYSIS; METHODOLOGY; PARKINSONISM; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOSIS; PSYCINFO; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT RESPONSE; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; CHOICE BEHAVIOR; FEMALE; HUMANS; MALE; PSYCHOTIC DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; WEIGHT GAIN;

EID: 77952994419     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.109.066217     Document Type: Article

References (48)

1. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321: 1371-1376
2. Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003; 361: 1581-1589 (Pubitemid 36578993)
3. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60: 553-564
4. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373: 31-41.
5. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223
6. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 63: 1079-1087 (Pubitemid 44498387)
7. Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, et al; CATIE Study Investigators. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 2006; 163: 2080-2089
8. Davies LM, Lewis S, Jones PB, Barnes TRE, Gaughran F, Hayhurst K, et al; CUtLASS team. Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. Br J Psychiatry 2007; 191: 14-22.
9. Large M, Farooq S, Nielssen O, Slade T. Relationship between gross domestic product and duration of untreated psychosis in low- and middle-income countries. Br J Psychiatry 2008; 193: 272-278
10. Lewis S, Lieberman J. CATIE and CUtLASS: can we handle the truth? Br J Psychiatry 2008; 192: 161-163
11. Robinson DG, Woerner MG, Alvir JM, Geisler S, Koreen A, Sheitman B, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999; 156: 544-549 (Pubitemid 29162974)
12. Oosthuizen P, Emsley R, Jadri Turner H, Keyter N. A randomized, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-episode psychosis. Int J Neuropsychopharmacol 2004; 7: 125-131 (Pubitemid 38823279)
13. Sanger TM, Lieberman JA, Tohen M, Grundy S, Beasley Jr C, Tollefson GD. Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry 1999; 156: 79-87. (Pubitemid 29034883)
14. Smith M, Hopkins D, Peveler RC, Holt RIG, Woodward M, Ismail K. First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry 2008; 192: 406-411 (Pubitemid 351809892)
15. Cotton SM, Lambert M, Schimmelmann BG, Foley DL, Morley KI, McGorry PD, Conus P. Gender differences in premorbid, entry, treatment, and outcome characteristics in a treated epidemiological sample of 661 patients with first episode psychosis. Schizophr Res 2009; 114: 17-24.
16. Rummel C, Hamann J, Kissling W, Leucht S. New generation antipsychotics for first episode schizophrenia. Cochrane Database Syst Rev 2003; 4: CD004410.
17. National Institute for Health and Clinical Excellence. Schizophrenia. NICE Clinical Guideline 82. NICE, 2009 (http://www.nice.org.uk/nicemedia/pdf/ CG82NICEGuideline.pdf).
18. Emsley R, Rabinowitz J, Medori R. Time course for antipsychotic treatment response in first-episode schizophrenia. Am J Psychiatry 2006; 163: 743-745 (Pubitemid 44464590)
19. Robinson DG, Woerner MG, Delman HM, Kane JM. Pharmacological treatments for first-episode schizophrenia. Schizophr Bull 2005; 31: 705-722
20. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188
21. Egger M, Davey Smith G. Systematic Reviews in Health Care: Meta-analysis in Context (2nd edn). BMJ Publishing Group, 2001.
22. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, et al; EUFEST study group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008; 371: 1085-1097
23. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634 (Pubitemid 27387172)
24. Emsley RA. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group. Schizophr Bull 1999; 25: 721-729
25. Mackeprang T, Kristiansen KT, Glenthøj BY. Effects of antipsychotics on prepulse inhibition of the startle response in drug-naïve schizophrenic patients. Biol Psychiatry 2002; 52: 863-873
26. Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey PD, Kopala L, et al; Early Psychosis Global Working Group. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry 2005; 162: 947-953
27. Wu RR, Zhao JP, Liu ZN, Zhai JG, Guo XF, Guo WB, et al. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology (Berl) 2006; 186: 572-578
28. Crespo-Facorro B, Pérez-Iglesias R, Ramirez-Bonilla M, Martínez-García O, Llorca J, Luis Vázquez-Barquero J. A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis. J Clin Psychiatry 2006; 67: 1511-1521 (Pubitemid 44787432)
29. Brewer WJ, Yücel M, Harrison BJ, McGorry PD, Olver J, Egan GF, et al. Increased prefrontal cerebral blood flow in first-episode schizophrenia following treatment: longitudinal positron emission tomography study. Aust N Z J Psychiatry 2007; 41: 129-135 (Pubitemid 46705624)
30. Gaebel W, Riesbeck M, Wölwer W, Klimke A, Eickhoff M, von Wilmsdorff M, et al; German Study Group on First-Episode Schizophrenia. Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry 2007; 68: 1763-1774
31. Lee SM, Chou YH, Li MH, Wan FJ, Yen MH. Effects of antipsychotics on cognitive performance in drug-naive schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 1101-1107
32. Saddichha S, Manjunatha N, Ameen S, Akhtar S.Diabetes and schizophrenia - effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia. Acta Psychiatr Scand 2008; 117: 342-347
33. de Haan L, van Bruggen M, Lavalaye J, Booij J, Dingemans PM, Linszen D. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. Am J Psychiatry 2003; 160: 303-309
34. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, et al; HGDH Study Group. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 2003; 160: 1396-1404
35. Bustillo JR, Rowland LM, Jung R, Brooks WM, Qualls C, Hammond R, et al. Proton Magnetic Resonance Spectroscopy During Initial Treatment With Antipsychotic Medication in Schizophrenia. Neuropsychopharmacology 2008; 33: 2456-2466
36. Lieberman JA, Phillips M, Gu H, Stroup S, Zhang P, Kong L, et al. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 2003; 28: 995-1003.
37. Wu RR, Zhao JP, Zhai JG, Guo XF, Guo WB. Sex difference in effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. J Clin Psychopharmacol 2007; 27: 374-379
38. Green AI, Lieberman JA, Hamer RM, Glick ID, Gur RE, Kahn RS, et al; HGDH Study Group. Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophr Res 2006; 86: 234-243
39. Glenthøj A, Glenthøj BY, Mackeprang T, Pagsberg AK, Hemmingsen RP, Jernigan TL, et al. Basal ganglia volumes in drug-naive first-episode schizophrenia patients before and after short-term treatment with either a typical or an atypical antipsychotic drug. Psychiatry Res 2007; 154: 199-208.
40. Leucht S, Kane JM, Etschel E, Kissling W, Hamann J, Engel RR. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology 2006; 31: 2318-2325
41. Alvarez-Jiménez M, González-Blanch C, Crespo-Facorro B, Hetrick S, Rodr?́guez-Sánchez JM, Pérez-Iglesias R, et al. Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal. CNS Drugs 2008; 22: 547-562 (Pubitemid 351822117)
42. Park S, Ross-Degnan D, Adams AS, Sabin J, Kanavos P, Soumerai SB. Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia: population-based study. Br J Psychiatry 2005; 187: 137-142 (Pubitemid 41139685)
43. Tyrer P, Kendall T. The spurious advance of antipsychotic drug therapy. Lancet 2009; 373: 4-5.
44. Margolis RL. Neuropsychiatric disorders: the choice of antipsychotics in schizophrenia. Nat Rev Neurol 2009; 5: 308-310.
45. Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009; 166: 152-163
46. Perez-Iglesias R, Crespo-Facorro B, Martinez-Garcia O, Ramirez-Bonilla ML, Alvarez-Jimenez M, Pelayo-Teran JM, et al. Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naïve population. Schizophr Res 2008; 99: 13-22. (Pubitemid 351255577)
47. Fagerlund B, Mackeprang T, Gade A, Glenthøj BY. Effects of low-dose risperidone and low-dose zuclopenthixol on cognitive functions in first-episode drug-naive schizophrenic patients. CNS Spectr 2004; 9: 364-374 (Pubitemid 38649725)
48. Möller HJ, Riedel M, Jäger M, Wickelmaier F, Maier W, Kühn KU, et al. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. Int J Neuropsychopharmacol 2008; 11: 985-987